226% return in 2 years: Zydus Lifesciences shares in focus as company inks licensing pact with Takeda

Zydus Lifesciences Share Price NSE, BSE: Shares of Zydus Lifesciences are in focus today after the firm said it had inked a licensing pact with Takeda to market a drug for the treatment of gastroesophageal reflux disease (GERD). The counter opened at Rs 1,184.60 and touched a high of Rs 1,189.60 before falling to Rs 1,168.80 amid selling pressure. Last seen, the scrip was trading at Rs 1170.50 - a 1.21 per cent fall from the previous close of Rs 1184.85 on the BSE. 

However, the stock is trading higher than the 5-day, 20-day, 50-day, 100-day and 200-day moving averages. The 52-week high and low of the counter are Rs 1,203.20 and Rs 564.05 respectively. The market cap of the company is Rs  1,17,729 crore.

Zydus Lifesciences Share Price History

According to BSE Analytics, the counter has given a multibagger return of over 226 per cent to investors in two years. In one year, the counter has gained over 94 per cent. So far this year, it has already given a positive return of 67.34 per cent.

Zydus Lifesciences in News

Zydus Lifesciences has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India, the drug firm said in a statement.

The drug will be marketed under the brand name Vault in the country, it added.

Under the terms of this agreement, Zydus will be marketing the drug in India.

"With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum," Zydus Lifesciences MD Sharvil Patel said.

Vonoprazan is approved by the DCGI (Drugs Controller General of India) for the treatment of adults with reflux esophagitis.

With PTI inputs